Data from the DEAR Real-World Study and Strategies for Optim

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Related Keywords

, Optimizing Care Across , Prostate Cancer , World Study , Optimizing Outcomes , Prostate Cancer Treatment , Prostate Cancer News , Prostate Cancer Updates , Prostate Cancer Therapies , Prostate Cancer Management , Prostate Cancer Year In Review , Prostate Cancer Year In Review 2023 ,